The latest Company announcements can be found here: Newsroom

The Company’s latest publications and presentations at industry conferences can be found here: Publications

The Company’s latest filings with the SEC can be found here: SEC Filings

Our Investors Relations page also offers a number of links and resources to additional information.

To get email alerts about the Company’s press releases and SEC filings via email, fill out your information and the notifications you wish to receive here.

1. Continue the Phase 2 (CLOVER) study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
2. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
3. Continue our work researching and developing a new or modified long-acting version of leronlimab.

The CLOVER study, CytoDyn’s Phase 2 study in Colorectal Cancer, completed enrollment in April 2026. Below are several resources where future updates and/or additional information about the study will be published/shared:

Newsroom

Publications

Clinicaltrials.gov - CLOVER - NCT06699836

The Our Science page contains information about leronlimab, including certain videos and illustrations meant to help explain its proposed mechanism(s) of action.

Access to Leronlimab Policy 

As an unapproved drug, leronlimab is not available to the general public. However, certain patients who are facing serious illnesses, and who have exhausted all available treatment options, may be able to receive early access to investigational drugs that haven’t yet been approved by government regulatory agencies. The FDA allows for two options for treating patients with an unapproved drug, biologic or test article outside of a clinical trial. One option is “Expanded Access.” The other option is “Right to Try.”

It is important that you first consult with your healthcare provider before inquiring about potential access to leronlimab. Your healthcare provider can then use the contact information below to submit access request(s) to the Company.

For inquiries relating to CytoDyn’s currently active Expanded Access Program (EAP) for patients with triple-negative breast cancer (TNBC): CytoDynEAP@wepclinical.com

For all other (eIND) requests: dai@cytodyn.com

For the most up-to-date information regarding The Right to Try Act, and/or potential access for patients who have been diagnosed with life-threatening diseases or conditions, have tried all approved treatment options, and are unable to participate in a clinical trial to access certain investigational treatment options, please visit FDA.gov and review its overview regarding “Right to Try” allowances. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try

WARNING: Leronlimab has not received regulatory approval from the FDA. The potential risks and benefits are not known. Doctors and patients should consider all possible benefits and risks before applying for expanded access (or right to try) to leronlimab.